microtubules

XRP44X (XRP 44X) is a potent inhibitor of Ras-Net (Elk-3) pathway.

Terflavoxate is a novel, orally active, semisynthetic statin microtubule inhibitor commonly used in combination with capecitabine. Terflavoxate is used in cancer research.

Myoseverin, an inducer of the reversible fission of multinucleated myotubes into mononucleated fragments, affecting the expression of a variety of growth factor, immunomodulatory, extracellular matrix-remodeling, and stress response genes, consistent with

Naphthazarin (5,8-Dihydroxy-1,4-naphthoquinone) is effective by various cellular mechanisms including oxidative stress, activation of mitochondrial apoptosis-inducing factor (AIF), depolymerization of microtubules, interference with lysosomal function and p53-dependent p21 activation. It triggers apoptosis and has anti-tumor effects

Microtubule stabilizer-1 (compound 69) is a microtubule (MT) stabilizer capable of crossing the blood-brain barrier. It increases the levels of acetylated α-tubulin (AcTub) and prevents the characteristic loss of neuronal microtubules observed after incubation with Okadaic acid. This compound is useful in researching Alzheimer's disease (AD) and related neurodegenerative tauopathies.

Compound 3l, a paclitaxel derivative known as Microtubule Stabilizing Agent-1, effectively enhances tubulin polymerization and demonstrates antitumor efficacy [1].

OSIP-486823(CP248) is a novel and potent microtubule disruptor with affinity for both protein kinase G (PKG) and microtubules.

Suprafenacine (N'-[(E)-(4-methylphenyl)methylidene]-4,5,6,7-tetrahydro-1H-indazole-3-carbohydrazide) is a cell-permeable microtubule destabilizer that induces cell cycle arrest and apoptosis in G2/M phase. Suprafenacine binds to microtubules and inhibits aggregation at the colchicine junction. Suprafenacine is selective for cancer cells, including drug-resistant cancer cells.

Cemadotin free base(LU103793 free base) is a novel anti-limiting peptide , an analog of Dolastatin 15, a naturally occurring cytotoxic peptide that blocks mitosis and inhibits microtubules (tubulin) with a Ki of 1 μM. Cemadotin is used in research against cancer.

Trimethylcolchicinic acid (N-Deacetylcolchiceine) is an orally available colchicine analog that binds to tubulin and inhibits its polymerization into microtubules, preventing cell division and having potential antitumor activity.

Eribulin (B1939) is a nonpaclitaxel microtubule kinetic inhibitor with anticancer activity that inhibits polymerization of microtubule protein subunits by preventing lengthening and shortening of microtubules during cell division.Eribulin is used in the study of metastatic breast cancer and solid tumors.

Vincristine sulfate is an alkaloidal natural product that binds to microtubule proteins and inhibits the formation of microtubules, thereby inhibiting mitosis in tumor cells. Vincristine sulfate is used as a microtubule destabilizing agent in research studies for the treatment of hematologic neoplasms such as leukemias and lymphomas, as well as in studies related to sarcomas in children.

Eribulin mesylate (E7389 mesylate) (E7389 mesylate) inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Eribulin mesylate (E7389 mesylate) is a microtubule targeting agent that is used in the treatment of metastatic breast cancer.

Larotaxel (XRP9881) is a taxane analogue with anticancer activity that promotes tubulin assembly and stabilizes microtubules, inducing apoptosis. It crosses the blood-brain barrier and has a higher affinity for Docetaxel than P-glycoprotein 1, making it useful for studying breast and bladder cancer.

Verubulin (MPC 6827) is a potent microtubule blocker with cytotoxic and potentially anticancer activity that disrupts newly formed blood vessels in xenografts, and can be used to image microtubules (MTs) using positron emission tomography (PET).

Mal-PEG2-VCP-Eribulin is a chemotherapeutic compound comprising an antibody-drug conjugate (ADC) linker (Mal-PEG2-VCP) and the microtubule inhibitor Eribulin[1]. This compound uniquely targets microtubules, offering a novel approach to cancer treatment. Eribulin is specifically utilized in creating targeted Eribulin-based drugs for antibody conjugates[1].

Tasidotin (also known as ILX-651) is an orally active synthetic derivative targeting microtubules, derived from the marine depsipeptide dolastatin-15.

Tubulin inhibitor 48 (compound 16) is an anticancer agent targeting microtubules. It exhibits IC50 values of 0.1 μM and 0.07 μM against LN-229 and Capan-1 cells, respectively.

MKLP2-IN-1 (compound 12a) is an inhibitor of MKLP2 that demonstrates excellent oral bioactivity. In vitro, MKLP2-IN-1 inhibits the ATPase activity stimulated by recombinant MKLP2 microtubules and, in a mouse Calu-6 lung cancer model, it effectively suppresses tumor growth.

Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.

Anticanceragent 270 (Compound 8e) is a microtubule protein inhibitor with an IC50 of 1.02 μM against MCF-7 breast cancer cells. It exerts significant antiproliferative activity on breast cancer cells through a dual mechanism of inducing apoptosis and destabilizing microtubules. Anticanceragent 270 is useful for cancer research.

Antitumor agent-190 (Compound 26) is a hexokinase 2 (Hexokinase2) inhibitor that exhibits significant antitumor activity by targeting both microtubules and hexokinase 2 (Hexokinase2), with an IC50 value of 0.764 μM against MD-MBA-231 cells. It effectively suppresses Hexokinase2 activity, resulting in the accumulation of reactive oxygen species (Reactive Oxygen Species) and disruption of mitochondrial membrane potential (MMP), thus promoting apoptosis and causing cell cycle arrest.

KIF2C-IN-1 (Compound 7S9) is a selective and potent small molecule inhibitor of KIF2C. It stabilizes the interaction between KIF2C and microtubule proteins, preventing the depolymerization of polyglutamylated microtubules. KIF2C-IN-1 enhances the cytotoxicity of Paclitaxel in Paclitaxel-resistant triple-negative breast cancer (TNBC) cells and, when combined with Paclitaxel, significantly reduces tumor growth in mouse models.

Tubulin/PARP-IN-1 (compound 14) is a dual PARP-tubulin inhibitor with anti-endometrial cancer activity. It exhibits inhibitory concentration (IC50) values of 74 nM for PARP1, 109 nM for PARP2, and 1.4 μM for microtubules/tubulin. Tubulin/PARP-IN-1 induces apoptosis and autophagy, causing cell cycle arrest at the G2/M phase.